RCUS · Arcus Biosciences, Inc.
Market Cap
$3.75B
Shares
127.33M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$247M
-4.3%
FY2025
Net Income
-$353M
-24.7%
FY2025
Operating Margin
-156.28%
-28.4pp
FY2025
Diluted EPS
-$3.29
-4.8%
FY2025
Operating Cash Flow
-$482M
-183.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $65M – $75M | $117M | $247MG | $258M | $117M | $112M | $383M | $78M | $15M | $8.35M | $1.41M | — | |
| — | $497M | $523M | $448M | $340M | $288M | $257M | $159M | $78.48M | $49.65M | $47.22M | $14.25M | |
| — | $106M | $110M | $120M | $117M | $104M | $72M | $43M | $25.23M | $13.57M | $7.64M | $3.94M | |
| — | $10M | $10M | $10M | $8M | $6M | $4M | $3M | $3.58M | $3.66M | $2.61M | $1.31M | |
| — | $603M | $633M | $588M | $457M | $392M | $329M | $202M | $103.71M | $63.21M | $54.85M | $18.18M | |
| — | -$486M | -$386M | -$330M | -$340M | -$280M | $54M | -$124M | -$88.71M | -$54.86M | -$53.44M | -$18.18M | |
| — | — | -156.28% | -127.91% | -290.6% | -250% | 14.1% | -158.97% | -591.39% | -656.76% | -3782.09% | — | |
| — | -$476M | -$376M | -$320M | -$332M | -$274M | $58M | -$121M | -$85.13M | -$51.2M | -$50.83M | -$16.87M | |
| — | $11M | $8M | $4M | $2M | $2M | — | — | — | — | — | — | |
| — | $26M | $33M | $48M | $39M | $14M | $1M | $1M | $4M | $5.27M | $359K | $212K | |
| — | — | — | — | — | — | — | -$613K | -$1.2M | -$886K | -$416K | $0 | |
| — | -$460M | -$353M | -$282M | -$301M | -$266M | $55M | -$123M | -$84.71M | — | — | — | |
| — | $0 | $0 | $1M | $6M | $1M | $2M | — | — | — | — | — | |
| — | -$460M | -$353M | -$283M | -$307M | -$267M | $53M | -$123M | -$84.71M | -$49.59M | -$53.08M | -$17.97M | |
| — | — | -142.91% | -109.69% | -262.39% | -238.39% | 13.84% | -157.69% | -564.73% | -593.73% | -3756.69% | — | |
| — | -$461M | -$353M | -$283M | -$300M | -$273M | $52M | -$123M | -$84.54M | -$49.66M | -$53.1M | -$18M | |
| USD/shares | — | -$3.89 | -$3.29 | -$3.14 | -$4.15 | -$3.71 | $0.76 | -$2.24 | -$1.93 | — | — | — |
| USD/shares | — | -$3.89 | -$3.29 | -$3.14 | -$4.15 | -$3.71 | $0.71 | -$2.24 | -$1.93 | — | — | — |
| shares | — | — | 107.4M | 90.1M | 74M | 72M | 69.3M | 54.8M | 43.83M | 36.36M | 3.89M | 3.37M |
| shares | — | — | 107.4M | 90.1M | 74M | 72M | 74M | 54.8M | 43.83M | 34.62M | 1.83M | 863.98K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2019: $94K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
31.63×
Peer median 6.60×
EV/EBIT
—
Peer median 22.45×
P/E (TTM)
—
Peer median 18.04×
Peer medians compare against the 210 similar-size Biotechnology companies (of 508 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $247,000,000 | $258,000,000 | $117,000,000 | $112,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| License and Development Services | $221,000,000 | $222,000,000 | $80,000,000 | — | — | — | — | — |
| Other Collaboration Revenue | $26,000,000 | $36,000,000 | $37,000,000 | $38,000,000 | $38,000,000 | $23,000,000 | $7,000,000 | — |
| Collaboration | — | — | — | — | — | $22,421,000 | $7,000,000 | $5,353,000 |
| Development Services For All Gilead Programs | — | — | — | — | $1,135,000 | — | — | — |
| Gilead Access Rights | — | — | — | — | $30,909,000 | $15,421,000 | — | — |
| Gilead Collaboration Access Rights | — | — | — | — | $31,000,000 | $16,000,000 | — | — |
| Gilead Collaboration License And RD Services | — | — | — | — | $1,000,000 | — | — | — |
| Gilead Collaboration License To Domvanalimab | — | — | — | — | $329,000,000 | — | — | — |
| Gilead Collaboration License To Zimberelimab | — | — | — | — | — | $55,000,000 | — | — |
| Gilead License to Domvanalimab | — | — | — | — | $328,838,000 | — | — | — |
| Gilead License to Zimberelimab | — | — | — | — | — | $55,096,000 | — | — |
| License and Development Services Revenue | — | — | — | $74,000,000 | $345,000,000 | $55,000,000 | — | — |
| Taiho Access Rights | — | — | — | — | $7,000,000 | $7,000,000 | $7,000,000 | — |
| Taiho Collaboration Access Rights | — | — | — | — | $7,000,000 | $7,000,000 | — | — |
| Taiho Collaboration Agreement | — | — | — | — | — | $7,000,000 | $7,000,000 | — |
| Taiho Collaboration License to Domvanalimab | — | — | — | — | $15,000,000 | — | — | — |
| Taiho Collaboration RD Services | — | — | — | — | $0 | — | — | — |
| Taiho License to Domvanalimab | — | — | — | — | $15,000,000 | — | — | — |
| Taiho License to Etrumadenant | — | — | — | — | — | — | — | $3,000,000 |
| Taiho License to Zimberelimab | — | — | — | — | — | — | $8,000,000 | — |
| License | — | — | — | — | $343,838,000 | $55,096,000 | $8,000,000 | — |
Key facts
CIK
1724521
CUSIP
03969F109
13F (30d)
199 filings
197 filers
Visit website
Investor relations